Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

163. Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition

Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition 27576605 2018 03 13 2018 11 13 2366-0058 42 1 2017 01 Abdominal radiology (New York) Abdom Radiol (NY) Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition. 290-297 10.1007/s00261-016-0881-x To compare image (...) quality and diagnostic performance for detecting local recurrence (LR) of prostate cancer after radical prostatectomy (RP) between standard dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and a high spatiotemporal resolution, continuously acquired Golden-angle RAdial Sparse Parallel acquisition employing compressed sensing reconstruction ("GRASP"). A search was conducted for prostate MRI examinations performed in patients with PSA ≥0.2 ng/mL after RP in whom follow-up evaluation

Abdominal radiology (New York)2017 Full Text: Link to full Text with Trip Pro

164. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis

Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis 27480976 2018 03 13 2018 11 13 2366-0058 42 1 2017 01 Abdominal radiology (New York) Abdom Radiol (NY) Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis. 271-277 10.1007/s00261-016-0851-3 Bone lesions on prostate MRI often raise concern about metastases. This study aimed to evaluate the prevalence (...) of bone metastases on staging prostate MRI and evaluate associations between their MRI features and clinical/pathologic characteristics. Retrospective, IRB-approved study of 3765 patients undergoing prostate MRI for newly diagnosed PCa between 2000 and 2014. The reference standard to calculate the prevalence of bone metastases was bone biopsy and/or ≥1-year follow-up after MRI. In a subsample of 228 patients, the MRI characteristics of bone lesions were recorded by two radiologists independently

Abdominal radiology (New York)2017 Full Text: Link to full Text with Trip Pro

165. In patients with localised prostate cancer, active surveillance is associated with better sexual function, urinary symptoms and bowel symptoms

In patients with localised prostate cancer, active surveillance is associated with better sexual function, urinary symptoms and bowel symptoms In patients with localised prostate cancer, active surveillance is associated with better sexual function, urinary symptoms and bowel symptoms | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we (...) use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In patients with localised prostate cancer, active surveillance is associated with better sexual

Evidence-Based Medicine (Requires free registration)2017

166. Do men with prostate cancer and their partners receive the information they need for optimal illness self-management in the immediate post-diagnostic phase?

Do men with prostate cancer and their partners receive the information they need for optimal illness self-management in the immediate post-diagnostic phase? 27981111 2016 12 16 2017 02 24 2347-5625 2 3 2015 Jul-Sep Asia-Pacific journal of oncology nursing Asia Pac J Oncol Nurs Do men with prostate cancer and their partners receive the information they need for optimal illness self-management in the immediate post-diagnostic phase? 169-175 To (a) determine whether the information provided to men (...) with prostate cancer and their partners in the immediate postdiagnostic phase met their needs; and (b) examine patient and partner satisfaction with the information received. Pre-intervention survey data from a pilot randomized controlled trial of a self-directed coping skills intervention involving 42 patients with prostate cancer, and their partners were collected to examine their psychosocial concerns/needs. The main concerns for patients and partners were psychosocial in nature such as managing emotions

Asia-Pacific journal of oncology nursing2016 Full Text: Link to full Text with Trip Pro

168. Vasectomy and risk of prostate cancer: population based matched cohort study.

Vasectomy and risk of prostate cancer: population based matched cohort study. OBJECTIVE: To determine the association between vasectomy and prostate cancer, adjusting for measures of health seeking behaviour. DESIGN: Population based matched cohort study. SETTING: Multiple validated healthcare databases in Ontario, Canada, 1994-2012. PARTICIPANTS: 326 607 men aged 20 to 65 who had undergone vasectomy were identified through physician billing codes and matched 1:1 on age (within two years), year (...) of cohort entry, comorbidity score, and geographical region to men who did not undergo a vasectomy. MAIN OUTCOMES MEASURES: The primary outcome was incident prostate cancer. Secondary outcomes were prostate cancer related grade, stage, and mortality. RESULTS: 3462 incident cases of prostate cancer were identified after a median follow-up of 10.9 years: 1843 (53.2%) in the vasectomy group and 1619 (46.8%) in the non-vasectomy group. In unadjusted analysis, vasectomy was associated with a slightly

BMJ2016

169. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent 27568654 2016 08 29 2017 03 04 1873-7560 71 4 2017 Apr European urology Eur. Urol. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. 618-629 S0302-2838(16)30470-5 10.1016/j.eururo.2016.08.003 To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy (...) & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on screening, diagnosis, and local treatment with curative intent of clinically localised prostate cancer (PCa). The working panel performed a literature review of the new data (2013-2015). The guidelines were updated and the levels of evidence and/or grades of recommendation were added based on a systematic review of the evidence. BRCA2 mutations have been added as risk factors for early and aggressive disease

EvidenceUpdates2016

170. Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy

Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy 27639533 2016 09 18 2017 03 04 1873-7560 71 4 2017 Apr European urology Eur. Urol. Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy. 596-605 S0302-2838(16)30617-0 10.1016/j.eururo.2016.09.007 Extended pelvic lymph node dissection (ePLND) is the gold standard for detecting lymph node (LN) metastases in prostate cancer (PCa). The benefit of sentinel node (...) diagnostic value over and above ePLND, although SNB appears to increase nodal yield by increasing the number of affected nodes when combined with ePLND. Thus, in high-risk disease it may be prudent to combine ePLND with SNB. This literature review showed a high diagnostic accuracy for sentinel node biopsy in detecting positive lymph nodes in prostate cancer, but further studies are needed to explore the effect of sentinel node biopsy on complications and oncologic outcome. Copyright © 2016 European

EvidenceUpdates2016

171. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer 27591931 2016 09 10 2017 03 04 1873-7560 71 4 2017 Apr European urology Eur. Urol. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. 630-642 S0302-2838(16)30469-9 10.1016/j.eururo.2016.08.002 To present a summary of the 2016 version of the European Association of Urology (EAU (...) ) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). The working panel performed a literature review of the new data (2013-2015). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature. Relapse after local therapy is defined by a rising

EvidenceUpdates2016

172. Radium-223 for Patients with Castration Resistant Prostate Cancer with Bone Metastases: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines

Radium-223 for Patients with Castration Resistant Prostate Cancer with Bone Metastases: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Radium-223 for Patients with Castration Resistant Prostate Cancer with Bone Metastases: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines | CADTH.ca Find the information you need Radium-223 for Patients with Castration Resistant Prostate Cancer with Bone Metastases: A Review of Clinical Effectiveness, Cost-effectiveness (...) and Guidelines Radium-223 for Patients with Castration Resistant Prostate Cancer with Bone Metastases: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Published on: October 31, 2016 Project Number: RC0817-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of Ra-223 in patients with castration resistant prostate cancer with bone metastases? What is the cost effectiveness of Ra-223 in patients

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

173. Urinary quality of life outcomes in men who were treated with image-guided intensity-modulated radiation therapy for prostate cancer

Urinary quality of life outcomes in men who were treated with image-guided intensity-modulated radiation therapy for prostate cancer 28740902 2018 11 13 2452-1094 1 4 2016 Oct-Dec Advances in radiation oncology Adv Radiat Oncol Urinary quality of life outcomes in men who were treated with image-guided intensity-modulated radiation therapy for prostate cancer. 310-316 10.1016/j.adro.2016.10.005 Quality of life (QoL) outcomes play a major role in the treatment selection for prostate cancer (CaP (...) ). We evaluated the urinary QoL outcomes in men who were treated with image-guided intensity-modulated radiation therapy (IG-IMRT) for CaP. We enrolled men who were diagnosed with CaP and underwent IG-IMRT in a large urological group practice into a prospectively maintained database. The typical radiation treatment dosage to prostates and seminal vesicles was 8100 cGy in 45 fractions. Urinary QoL was self-assessed using the standardized incontinence grade and International Prostate Symptom Score

Advances in radiation oncology2016 Full Text: Link to full Text with Trip Pro

174. Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer 28740901 2018 11 13 2452-1094 1 4 2016 Oct-Dec Advances in radiation oncology Adv Radiat Oncol Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and high-risk prostate cancer. 300-309 10.1016/j.adro.2016.10.006 (...) The addition of androgen deprivation therapy (ADT) to conventional radiation therapy improves overall survival (OS) in intermediate- and high-risk prostate cancer. The benefit of ADT to added to dose-escalated radiotherapy is less clear. The aim of this study was to report disease control outcomes and to identify prognostic variables associated with favorable outcomes in patients with intermediate- and high-risk prostate cancer treated with dose-escalated radiation therapy without ADT. From September 2001

Advances in radiation oncology2016 Full Text: Link to full Text with Trip Pro

175. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II

ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II 28740916 2018 11 13 2452-1094 2 1 2017 Jan-Mar Advances in radiation oncology Adv Radiat Oncol ACR Appropriateness Criteria ® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. 62-84 10.1016/j.adro.2016.10.002 Expert Panel on Radiation Oncology-Prostate: Zaorsky Nicholas G NG Fox Chase Cancer Center (...) 15066296 Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9 22330997 Med Phys. 2007 Oct;34(10):4041-63 17985650 Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1260-9 19251098 Technol Cancer Res Treat. 2010 Dec;9(6):575-82 21070079 Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e363-70 22633552 Clin Prostate Cancer. 2002 Sep;1(2):97-104 15046700 Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):911-8 21420244 Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1105-11 12829148 Radiother Oncol. 2011 Sep;100

Advances in radiation oncology2016 Full Text: Link to full Text with Trip Pro

176. Advances in the management of castration resistant prostate cancer.

Advances in the management of castration resistant prostate cancer. Docetaxel based chemotherapy showed survival benefit and emerged as the mainstay of treatment for castration resistant prostate cancer (CRPC) in 2004. However, therapeutic options have expanded rapidly since 2011. The spectrum of new agents is broad and includes drugs that target the androgen axis (enzalutamide, abiraterone), immunotherapy (sipuleucel-T), bone seeking radionuclides (radium-223), and second line chemotherapy (...) (cabazitaxel). In addition, new agents have been developed to reduce skeletal related events (denosumab). Given that docetaxel was the standard first line treatment for metastatic CRPC, the newer oral agents that affect the androgen axis were initially approved in the post-docetaxel setting. However, subsequent randomized trials have led to their approval in the pre-chemotherapy setting as well. Patients with CRPC are clinically heterogeneous, ranging from patients who are asymptomatic and do not have

BMJ2016

180. Proton beam therapy for prostate cancer

Proton beam therapy for prostate cancer Proton beam therapy for prostate cancer Proton beam therapy for prostate cancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Proton beam therapy for prostate cancer. Lansdale: HAYES, Inc.. Directory Publication. 2016 Authors' conclusions Proton beam therapy (PBT) is a type of external radiation (...) for prostate cancer patients? Does PBT cause fewer complications than other types of radiation therapy? Have definitive patient selection criteria for PBT for prostate cancer been established? Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Humans; Male; Prostatic Neoplasms; Proton Therapy; Radiotherapy Dosage Language Published English Country of organisation United States English summary An English language summary is available. Address

Health Technology Assessment (HTA) Database.2016